Aimmune Therapeutics (NASDAQ: AIMT) and Repligen Corporation (NASDAQ:RGEN) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, dividends, institutional ownership, analyst recommendations, earnings and profitability.

Earnings and Valuation

This table compares Aimmune Therapeutics and Repligen Corporation’s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Aimmune Therapeutics N/A N/A -$106.22 million ($2.25) -10.15
Repligen Corporation $113.32 million 14.18 $29.54 million $0.51 84.37

Repligen Corporation has higher revenue and earnings than Aimmune Therapeutics. Aimmune Therapeutics is trading at a lower price-to-earnings ratio than Repligen Corporation, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Aimmune Therapeutics and Repligen Corporation, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aimmune Therapeutics 0 0 2 0 3.00
Repligen Corporation 0 2 2 0 2.50

Aimmune Therapeutics presently has a consensus target price of $36.67, indicating a potential upside of 60.61%. Repligen Corporation has a consensus target price of $41.00, indicating a potential downside of 4.72%. Given Aimmune Therapeutics’ stronger consensus rating and higher probable upside, research analysts clearly believe Aimmune Therapeutics is more favorable than Repligen Corporation.

Risk & Volatility

Aimmune Therapeutics has a beta of -1.1, suggesting that its stock price is 210% less volatile than the S&P 500. Comparatively, Repligen Corporation has a beta of 1.21, suggesting that its stock price is 21% more volatile than the S&P 500.

Institutional & Insider Ownership

72.9% of Aimmune Therapeutics shares are held by institutional investors. Comparatively, 97.9% of Repligen Corporation shares are held by institutional investors. 24.6% of Aimmune Therapeutics shares are held by company insiders. Comparatively, 1.5% of Repligen Corporation shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares Aimmune Therapeutics and Repligen Corporation’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Aimmune Therapeutics N/A -44.53% -42.00%
Repligen Corporation 15.61% 9.90% 5.93%

Summary

Repligen Corporation beats Aimmune Therapeutics on 8 of the 11 factors compared between the two stocks.

About Aimmune Therapeutics

Aimmune Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services. The Company’s lead CODIT product candidate, AR101, is an investigational biologic for the treatment of patients with peanut allergy. The Company has initiated Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults (PALISADE), its Phase III registration trial of AR101. The Company is in the process of evaluating additional delivery forms for AR101 for the maintenance phase.

About Repligen Corporation

Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company’s portfolio includes protein products, chromatography products, and filtration products. It provides Protein A ligands, a component of Protein A chromatography resins (media) used in the purification of virtually all monoclonal antibody (mAb)-based drugs on the market or in development. Its chromatography portfolio includes various products used in the downstream purification and quality control of biological drugs. Its OPUS pre-packed chromatography columns (PPCs) are used in the purification of clinical-stage biologics. Its filtration products include XCell Alternating Tangential Flow (ATF) Systems and Sius tangential flow filtration (TFF) cassettes. Sius TFF cassettes are used to concentrate clinical and commercial-stage biologic drugs.

Receive News & Stock Ratings for Aimmune Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics Inc. and related stocks with our FREE daily email newsletter.